Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Amylin Pharmaceuticals, Inc. Eli Lilly and Company |
---|---|
Information provided by: | Amylin Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00082381 |
This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus, Type 2 |
Drug: AC2993 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin |
Ages Eligible for Study: | 30 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | H8O-MC-GWAA |
Study First Received: | May 6, 2004 |
Last Updated: | November 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00082381 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Diabetes Insulin glargine comparator Amylin Lilly |
Metabolic Diseases Exenatide Amylin Metformin Diabetes Mellitus Endocrine System Diseases Insulin |
Hypoglycemic Agents Diabetes Mellitus, Type 2 Glargine Endocrinopathy Glucose Metabolism Disorders Metabolic Disorder |
Hypoglycemic Agents Metabolic Diseases Exenatide Physiological Effects of Drugs Diabetes Mellitus, Type 2 |
Glargine Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Pharmacologic Actions |